ITBO20120368A1 - Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. - Google Patents

Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. Download PDF

Info

Publication number
ITBO20120368A1
ITBO20120368A1 IT000368A ITBO20120368A ITBO20120368A1 IT BO20120368 A1 ITBO20120368 A1 IT BO20120368A1 IT 000368 A IT000368 A IT 000368A IT BO20120368 A ITBO20120368 A IT BO20120368A IT BO20120368 A1 ITBO20120368 A1 IT BO20120368A1
Authority
IT
Italy
Prior art keywords
rifaximin
crystals
amino acids
compositions
water
Prior art date
Application number
IT000368A
Other languages
English (en)
Italian (it)
Inventor
Dario Braga
Laura Chelazzi
Fabrizia Grepioni
Giuseppe Claudio Viscomi
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46939741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITBO20120368(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Priority to IT000368A priority Critical patent/ITBO20120368A1/it
Priority to ES13739813.7T priority patent/ES2691971T3/es
Priority to MX2014015799A priority patent/MX366193B/es
Priority to PT13739813T priority patent/PT2870163T/pt
Priority to CN201380033964.XA priority patent/CN104395322B/zh
Priority to EA201492126A priority patent/EA028769B1/ru
Priority to PL13739813T priority patent/PL2870163T3/pl
Priority to NZ703120A priority patent/NZ703120A/en
Priority to SG11201408277UA priority patent/SG11201408277UA/en
Priority to DK13739813.7T priority patent/DK2870163T3/en
Priority to EP16187004.3A priority patent/EP3127909A1/en
Priority to KR1020157000175A priority patent/KR101880255B1/ko
Priority to PCT/IB2013/055448 priority patent/WO2014006576A1/en
Priority to BR112015000088A priority patent/BR112015000088B1/pt
Priority to EP13739813.7A priority patent/EP2870163B1/en
Priority to US13/935,331 priority patent/US9452157B2/en
Priority to CA2874815A priority patent/CA2874815C/en
Priority to IN11207DEN2014 priority patent/IN2014DN11207A/en
Priority to AU2013285085A priority patent/AU2013285085B2/en
Priority to JP2015519474A priority patent/JP6150888B2/ja
Priority to UAA201412919A priority patent/UA114512C2/uk
Publication of ITBO20120368A1 publication Critical patent/ITBO20120368A1/it
Priority to IL235992A priority patent/IL235992B/en
Priority to ZA2014/08990A priority patent/ZA201408990B/en
Priority to TN2014000530A priority patent/TN2014000530A1/fr
Priority to CL2015000019A priority patent/CL2015000019A1/es
Priority to US15/235,070 priority patent/US20170189385A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
IT000368A 2012-07-06 2012-07-06 Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. ITBO20120368A1 (it)

Priority Applications (26)

Application Number Priority Date Filing Date Title
IT000368A ITBO20120368A1 (it) 2012-07-06 2012-07-06 Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
UAA201412919A UA114512C2 (uk) 2012-07-06 2013-07-03 Фармацевтичні композиції, які містять рифаксимін та амінокислоти, їх спосіб отримання та застосування
PCT/IB2013/055448 WO2014006576A1 (en) 2012-07-06 2013-07-03 Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof
EP13739813.7A EP2870163B1 (en) 2012-07-06 2013-07-03 Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof
PT13739813T PT2870163T (pt) 2012-07-06 2013-07-03 Composições farmacêuticas compreendendo rifaximina e aminoácidos, método de preparação e utilização dos mesmos
CN201380033964.XA CN104395322B (zh) 2012-07-06 2013-07-03 含有利福昔明和氨基酸的药用组合物、其制备方法和用途
EA201492126A EA028769B1 (ru) 2012-07-06 2013-07-03 Фармацевтические композиции, содержащие рифаксимин и аминокислоты, способ их получения и их применение
PL13739813T PL2870163T3 (pl) 2012-07-06 2013-07-03 Kompozycje farmaceutyczne zawierające rifaksyminę i aminokwasy, sposób otrzymywania oraz ich zastosowanie
NZ703120A NZ703120A (en) 2012-07-06 2013-07-03 Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof
SG11201408277UA SG11201408277UA (en) 2012-07-06 2013-07-03 Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof
DK13739813.7T DK2870163T3 (en) 2012-07-06 2013-07-03 PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMIN AND AMINO ACIDS, METHOD OF PREPARING AND USING THEREOF
EP16187004.3A EP3127909A1 (en) 2012-07-06 2013-07-03 Crystalline forms of rifaximin and their preparation in the presence of amino acids
KR1020157000175A KR101880255B1 (ko) 2012-07-06 2013-07-03 리팍시민 및 아미노산을 포함하는 약학적 조성물, 이의 제조방법 및 용도
ES13739813.7T ES2691971T3 (es) 2012-07-06 2013-07-03 Composiciones farmacéuticas que comprenden rifaximina y aminoácidos, procedimiento de preparación y sus usos
BR112015000088A BR112015000088B1 (pt) 2012-07-06 2013-07-03 composições farmacêuticas compreendendo rifamixinaa e aminoácidos, método de preparação e uso das mesmas
MX2014015799A MX366193B (es) 2012-07-06 2013-07-03 Composiciones farmaceuticas que comprenden rifaximina y aminoacidos, metodo de preparacion y uso de las mismas.
US13/935,331 US9452157B2 (en) 2012-07-06 2013-07-03 Pharmaceutical compositions comprising rifaximin and amino acids, preparation methods and use thereof
CA2874815A CA2874815C (en) 2012-07-06 2013-07-03 Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof.
IN11207DEN2014 IN2014DN11207A (enExample) 2012-07-06 2013-07-03
AU2013285085A AU2013285085B2 (en) 2012-07-06 2013-07-03 Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof
JP2015519474A JP6150888B2 (ja) 2012-07-06 2013-07-03 リファキシミン及びアミノ酸を含む医薬組成物、その調製方法及びその使用
IL235992A IL235992B (en) 2012-07-06 2014-11-30 Pharmaceutical preparations containing rifaximin and amino acids, a method for their preparation and use
ZA2014/08990A ZA201408990B (en) 2012-07-06 2014-12-08 Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof
TN2014000530A TN2014000530A1 (en) 2012-07-06 2014-12-24 Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof
CL2015000019A CL2015000019A1 (es) 2012-07-06 2015-01-06 Composicion farmaceutica que comprende rifaximina cristalina, polimorfa o amorfa, como un hidrato o solvato y/o en una mezcla de la misma y uno o mas aminoacidos; procedimiento de preparacion de la composicion; cristales de rifaximina; su procedimiento de preparacion.
US15/235,070 US20170189385A1 (en) 2012-07-06 2016-08-11 Pharmaceutical compositions comprising rifaximin and amino acids, preparation methods and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000368A ITBO20120368A1 (it) 2012-07-06 2012-07-06 Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.

Publications (1)

Publication Number Publication Date
ITBO20120368A1 true ITBO20120368A1 (it) 2014-01-07

Family

ID=46939741

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000368A ITBO20120368A1 (it) 2012-07-06 2012-07-06 Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.

Country Status (24)

Country Link
US (2) US9452157B2 (enExample)
EP (2) EP2870163B1 (enExample)
JP (1) JP6150888B2 (enExample)
KR (1) KR101880255B1 (enExample)
CN (1) CN104395322B (enExample)
AU (1) AU2013285085B2 (enExample)
BR (1) BR112015000088B1 (enExample)
CA (1) CA2874815C (enExample)
CL (1) CL2015000019A1 (enExample)
DK (1) DK2870163T3 (enExample)
EA (1) EA028769B1 (enExample)
ES (1) ES2691971T3 (enExample)
IL (1) IL235992B (enExample)
IN (1) IN2014DN11207A (enExample)
IT (1) ITBO20120368A1 (enExample)
MX (1) MX366193B (enExample)
NZ (1) NZ703120A (enExample)
PL (1) PL2870163T3 (enExample)
PT (1) PT2870163T (enExample)
SG (1) SG11201408277UA (enExample)
TN (1) TN2014000530A1 (enExample)
UA (1) UA114512C2 (enExample)
WO (1) WO2014006576A1 (enExample)
ZA (1) ZA201408990B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
AU2015260837B2 (en) 2014-05-12 2019-02-28 Alfasigma S.P.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
WO2016204474A2 (ko) * 2015-06-18 2016-12-22 주식회사대성미생물연구소 리팍시민 결정체를 포함하는 동물 장염 치료용 수의학적 조성물
US11793222B2 (en) 2016-02-03 2023-10-24 Firmenich Sa Solutions and dispersions of amide compounds
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
MX387893B (es) * 2018-04-18 2025-03-19 Alparis Sa De Cv Nuevas fases solidas de rifaximina.
WO2020208140A1 (en) * 2019-04-12 2020-10-15 Sandoz Ag Rifaximin-containing granules
KR102154309B1 (ko) 2019-07-05 2020-09-09 주식회사 비오엑스 테이프 없이 포장가능한 포장상자
MX427410B (es) 2019-09-24 2025-10-13 Bausch Health Ireland Ltd Formulaciones liquidas de rifaximina
KR102252978B1 (ko) 2019-12-11 2021-05-18 주식회사 비오엑스 테이프 없이 포장가능한 포장상자
KR102312848B1 (ko) 2019-12-11 2021-10-15 주식회사 비오엑스 테이프 없이 포장가능한 포장상자
KR102182587B1 (ko) 2020-01-22 2020-11-24 주식회사 비오엑스 밀폐구조를 갖는 포장상자
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
KR20220151991A (ko) 2021-05-07 2022-11-15 주식회사 비오엑스 테이프 없이 포장 가능한 포장상자
KR102674188B1 (ko) 2022-01-13 2024-06-12 주식회사 비오엑스 테이프 없이 포장 가능한 포장상자
CN117447487A (zh) * 2022-07-19 2024-01-26 重庆圣华曦药业股份有限公司 一种利福昔明的纯化方法及其在利福昔明片剂中的应用
KR102756705B1 (ko) 2024-07-11 2025-01-21 주식회사 비오엑스 테이프 없이 포장가능한 보온, 보냉용 포장상자

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050196418A1 (en) * 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
WO2006094737A2 (en) * 2005-03-07 2006-09-14 Alfa Wassermann S.P.A. Gastroresistant pharmaceutical formulations containing rifaximin
US20110105550A1 (en) * 2008-02-25 2011-05-05 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
WO2011088688A1 (zh) * 2010-01-19 2011-07-28 南京泛太化工医药研究所 以氨基酸为稳定剂的聚合物胶束载药系统
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2043847A1 (enExample) 1969-05-30 1971-02-19 Takeda Chemical Industries Ltd
CH571064A5 (en) 1973-03-01 1975-12-31 Archifar Ind Chim Trentino Recovery of rieamycin from broths - by oxidn to an insol form
US4267274A (en) 1973-04-26 1981-05-12 Gruppo Lepetit S.P.A. Streptomyces mediterranei mutant capable of production of rifamycin B
GB1470426A (en) 1974-08-30 1977-04-14 Lepetit Spa Rifamycins
JPS6021570B2 (ja) * 1978-07-04 1985-05-28 三共株式会社 ド−パ類の高濃度製剤の製法
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
JPS57209211A (en) * 1981-06-18 1982-12-22 Shiseido Co Ltd Antimicrobial composition
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US4816568A (en) 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
GB8816620D0 (en) 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
CA2082809C (en) 1990-06-29 1995-10-17 Marino Nebuloni Pure crystalline form of rifapentine
US5284512A (en) 1991-03-06 1994-02-08 Donlar Corporation Polyaspartic acid and its salts for dispersing suspended solids
DE10399015I1 (de) 1991-12-20 2012-05-03 Novo Nordisk As Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
AU3582893A (en) 1992-01-13 1993-08-03 Pitman-Moore, Inc. Delayed release device for transition metal/protein complexes
EP0639984A1 (en) 1992-04-07 1995-03-01 Mallinckrodt Veterinary, Inc. Lyophilized somatotropin formulations
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
JP4195728B2 (ja) 1996-10-16 2008-12-10 ナポ ファーマシューティカルズ，インコーポレーテッド プロアントシアニジンポリマー止瀉組成物の腸溶製剤
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6042816A (en) 1998-08-19 2000-03-28 The Gillette Company Enhanced antiperspirant salts stabilized with calcium and concentrated aqueous solutions of such salts
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CA2426393C (en) 2000-10-31 2012-05-29 Ciba Specialty Chemicals Holding Inc. Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US6902723B2 (en) 2003-08-14 2005-06-07 The Gillette Company Enhanced efficacy antiperspirant compositions containing strontium
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
EP2069363B1 (en) 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
ES2798253T3 (es) 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
WO2009008006A2 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
JP5755878B2 (ja) 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
BRPI0920465A2 (pt) * 2008-10-02 2018-03-20 Salix Pharmaceuticals, Inc. metodo de tratamento de encefalopatia hepática
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
WO2010044093A1 (en) 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
US8916193B2 (en) 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes
IT1397617B1 (it) 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
PT3192500T (pt) 2009-05-19 2021-01-05 Neuroderm Ltd Composições para a administração contínua de inibidores da dopa decarboxilase
EP2493471B1 (en) 2009-10-26 2019-11-27 Thomas Julius Borody Novel enteric combination therapy
RU2012121599A (ru) 2009-10-27 2013-12-10 Люпин Лимитед Твердая дисперсия рифаксимина
WO2011061748A1 (en) 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
BR112012012315A2 (pt) 2009-11-23 2018-10-16 Cipla Ltd composição farmacêutica para administração retal tópica na forma de espuma, uso de uma composição farmacêutica, método para tratamento, prevenção ou alívio de um dustúrbio no reto, cólon, íleo terminal ou anus, processo para fabricação de uma composição farmacêutica contendo rifaximina, uso de silicone e dispensador para composição farmacêutica
EP2503989A2 (en) 2009-11-23 2012-10-03 Cipla Limited Topical foam composition
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
AU2011225810B2 (en) 2010-03-10 2014-11-06 Lupin Limited Rifaximin ready-to-use suspension
WO2011153444A1 (en) 2010-06-03 2011-12-08 Salix Pharmaceuticals, Ltd New forms of rifaximin and uses thereof
CA2802874A1 (en) 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
SMT202000390T1 (it) 2010-07-12 2020-09-10 Salix Pharmaceuticals Inc Formulazioni di rifaximina e loro usi
CN103221032A (zh) 2010-09-13 2013-07-24 西普拉有限公司 药物组合物
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
WO2012109605A2 (en) 2011-02-11 2012-08-16 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
CA2834829A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
AU2013212008A1 (en) 2012-01-25 2014-07-10 Alfa Wassermann S.P.A. Rifaximin derivative and uses thereof
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
ITMI20131307A1 (it) 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A Processo per la preparazione di refaximina k

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050196418A1 (en) * 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
WO2006094737A2 (en) * 2005-03-07 2006-09-14 Alfa Wassermann S.P.A. Gastroresistant pharmaceutical formulations containing rifaximin
US20110105550A1 (en) * 2008-02-25 2011-05-05 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
WO2011088688A1 (zh) * 2010-01-19 2011-07-28 南京泛太化工医药研究所 以氨基酸为稳定剂的聚合物胶束载药系统
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ATSUSHI HIRANO ET AL: "Arginine-Assisted Solubilization System for Drug Substances: Solubility Experiment and Simulation", THE JOURNAL OF PHYSICAL CHEMISTRY B, vol. 114, no. 42, 28 October 2010 (2010-10-28), pages 13455 - 13462, XP055046746, ISSN: 1520-6106, DOI: 10.1021/jp101909a *

Also Published As

Publication number Publication date
PT2870163T (pt) 2018-11-12
MX366193B (es) 2019-07-01
KR20150035998A (ko) 2015-04-07
US20140079783A1 (en) 2014-03-20
CL2015000019A1 (es) 2015-06-26
ES2691971T3 (es) 2018-11-29
SG11201408277UA (en) 2015-02-27
MX2014015799A (es) 2015-03-05
UA114512C2 (uk) 2017-06-26
BR112015000088A8 (pt) 2017-12-26
US9452157B2 (en) 2016-09-27
WO2014006576A1 (en) 2014-01-09
CN104395322B (zh) 2017-05-10
ZA201408990B (en) 2016-08-31
EA201492126A1 (ru) 2015-06-30
NZ703120A (en) 2016-11-25
EP3127909A1 (en) 2017-02-08
US20170189385A1 (en) 2017-07-06
IL235992B (en) 2018-10-31
AU2013285085A1 (en) 2015-01-15
PL2870163T3 (pl) 2019-03-29
DK2870163T3 (en) 2018-10-29
BR112015000088A2 (pt) 2017-06-27
TN2014000530A1 (en) 2016-03-30
IN2014DN11207A (enExample) 2015-10-02
CA2874815A1 (en) 2014-01-09
JP6150888B2 (ja) 2017-06-21
IL235992A0 (en) 2015-02-01
CA2874815C (en) 2019-09-17
BR112015000088B1 (pt) 2020-04-28
KR101880255B1 (ko) 2018-07-20
EP2870163A1 (en) 2015-05-13
AU2013285085B2 (en) 2017-06-08
CN104395322A (zh) 2015-03-04
EP2870163B1 (en) 2018-09-19
EA028769B1 (ru) 2017-12-29
JP2015522010A (ja) 2015-08-03

Similar Documents

Publication Publication Date Title
AU2013285085B2 (en) Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof
US8541443B2 (en) Crystal of diamine derivative and method of producing same
US9737610B2 (en) Formulations of rifaximin and uses thereof
US8227482B1 (en) Forms of rifaximin and uses thereof
JP2013520427A (ja) リファキシミンの型およびその使用
ES2952770T3 (es) Formas de estado sólido de apalutamida
JP2011513243A (ja) リファキシミンの型およびその使用
KR20130086338A (ko) 리팍시민의 신규한 형태들 및 이들의 용도
WO2012114325A1 (en) Polymorphs of asenapine maleate
ES2924432T3 (es) Polimorfos cristalinos de un agonista del receptor de la acetilcolina muscarínica
TWI705065B (zh) 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途
JP2013184902A (ja) リファキシミン含有結晶
CN104402908B (zh) 头孢西丁钠化合物实体及其组合物和用途
HK1228392A1 (en) Crystalline forms of rifaximin and their preparation in the presence of amino acids
CN107663198A (zh) 奥美沙坦酯及其制备方法和用途
EP3368527A1 (en) Palbociclib salts